Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Molecular target testing in a preclinical culture assay of Emery Dreifuss muscular dystrophy
FY 2021-22
Summary
An emerging strategy of regenerative medicine focuses on harnessing the function of resident stem cell populations to heal tissue injuries and cure disease, a process called endogenous repair. For instance, in cases of major muscle damage such as muscular dystrophy disorders, muscle stem cells (MuSCs) reside in the muscle tissue, but have reduced regenerative abilities that lead to degeneration. Using a tissue engineering approach, the goal of this work is to generate and validate a human model of Emery Dreifuss muscular dystrophy (EDMD) to elucidate the cellular and molecular mechanisms underlying EDMD MuSC pathophysiology. Our lab has developed a 3D mini-muscle tissue platform that recapitulates MuSC-mediated skeletal muscle repair called Muscle Endogenous Repair (MEndR), whereby upon muscle injury, the MuSCs accurately recapitulate the in vivo endogenousrepair process. We will first optimize our MEndR platform for EDMD patient-derived immortalized human myoblasts, and subsequently will characterize the parameters of muscle fiber health and endogenous regeneration between healthy and EDMD myoblasts, such as myotube morphology, nuclei fusion index, as well as the size and proliferative state of the resident MuSC-like population. We hypothesize the EDMD patient-derived myoblasts will have impaired endogenous repair capabilities, and that these defects can be recapitulated in our MEndR platform. Thus, we will use the MEndR assay to test candidate biomolecules that rescue the impaired regenerative defects observed in the EDMD myoblasts. This research will fill a fundamental gap in knowledge by generating a first-class skeletal muscle tissue platform for human myoblasts and will identify therapeutic molecules that stimulate MuSC activity and endogenous repair in EDMD.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
466912
Name
Gorospe Kristyna A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Molecular target testing in a preclinical culture assay of Emery Dreifuss muscular dystrophy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cell Therapy; Emery Dreifuss Muscular Dystrophy; Endogenous Repair; In Vitro Assay; Linc Complex; Muscle Stem Cells; Musculoskeletal Models; Regenerative Medicine; Skeletal Muscle Regeneration; Tissue Engineering
Abstract
An emerging strategy of regenerative medicine focuses on harnessing the function of resident stem cell populations to heal tissue injuries and cure disease, a process called endogenous repair. For instance, in cases of major muscle damage such as muscular dystrophy disorders, muscle stem cells (MuSCs) reside in the muscle tissue, but have reduced regenerative abilities that lead to degeneration. Using a tissue engineering approach, the goal of this work is to generate and validate a human model of Emery Dreifuss muscular dystrophy (EDMD) to elucidate the cellular and molecular mechanisms underlying EDMD MuSC pathophysiology. Our lab has developed a 3D mini-muscle tissue platform that recapitulates MuSC-mediated skeletal muscle repair called Muscle Endogenous Repair (MEndR), whereby upon muscle injury, the MuSCs accurately recapitulate the in vivo endogenousrepair process. We will first optimize our MEndR platform for EDMD patient-derived immortalized human myoblasts, and subsequently will characterize the parameters of muscle fiber health and endogenous regeneration between healthy and EDMD myoblasts, such as myotube morphology, nuclei fusion index, as well as the size and proliferative state of the resident MuSC-like population. We hypothesize the EDMD patient-derived myoblasts will have impaired endogenous repair capabilities, and that these defects can be recapitulated in our MEndR platform. Thus, we will use the MEndR assay to test candidate biomolecules that rescue the impaired regenerative defects observed in the EDMD myoblasts. This research will fill a fundamental gap in knowledge by generating a first-class skeletal muscle tissue platform for human myoblasts and will identify therapeutic molecules that stimulate MuSC activity and endogenous repair in EDMD.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gorospe, Kristyna A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~